Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study.

[1]  G. Breen,et al.  Genetic predisposition to advanced biological ageing increases risk for childhood-onset recurrent major depressive disorder in a large UK sample , 2017, Journal of affective disorders.

[2]  A. Strafella,et al.  Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease , 2018, Front. Neurol..

[3]  J. R. Zapata.  onset , 2018, Speech Processing.

[4]  W. Poewe,et al.  Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies , 2018, Acta Neuropathologica Communications.

[5]  A. Hiwatashi,et al.  Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study , 2017, Journal of Neuroinflammation.

[6]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[7]  Yan Yang,et al.  Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis , 2017, Neurological Sciences.

[8]  B. Mollenhauer,et al.  Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.

[9]  M. Saraiva,et al.  Balancing the immune response in the brain: IL-10 and its regulation , 2016, Journal of Neuroinflammation.

[10]  T. Matsukawa,et al.  Plasma Coenzyme Q10 Levels in Patients With Multiple System Atrophy. , 2016, JAMA neurology.

[11]  T. Tokuda,et al.  Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy , 2016, PloS one.

[12]  C. Limatola,et al.  Fractalkine in the nervous system: neuroprotective or neurotoxic molecule? , 2015, Annals of the New York Academy of Sciences.

[13]  B. Bloem,et al.  CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders , 2015, Front. Neurol..

[14]  G. Wenning,et al.  Multiple-system atrophy. , 2015, The New England journal of medicine.

[15]  O. Hansson,et al.  Flt3 ligand does not differentiate between Parkinsonian disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.

[16]  Y. Surova,et al.  Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy , 2013, PloS one.

[17]  P. Bickford,et al.  The Soluble Isoform of CX3CL1 Is Necessary for Neuroprotection in a Mouse Model of Parkinson's Disease , 2012, The Journal of Neuroscience.

[18]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[19]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[20]  P. Bickford,et al.  CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease , 2011, Journal of Neuroinflammation.

[21]  S. Miller,et al.  CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function , 2011, Journal of leukocyte biology.

[22]  E. Tolosa,et al.  Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[23]  A. Rombos,et al.  Circulating interleukin‐10 and interleukin‐12 in Parkinson’s disease , 2009, Acta neurologica Scandinavica.

[24]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[25]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[26]  A. Stępień,et al.  Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.

[27]  E. Arenas,et al.  The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons. , 2008, Experimental cell research.

[28]  W. Poewe,et al.  Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[29]  Steffen Jung,et al.  Control of microglial neurotoxicity by the fractalkine receptor , 2006, Nature Neuroscience.

[30]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[31]  Á. Chamorro,et al.  Levels of Anti-Inflammatory Cytokines and Neurological Worsening in Acute Ischemic Stroke , 2003, Stroke.

[32]  L. Stefanis,et al.  Regulation of α‐synuclein by bFGF in cultured ventral midbrain dopaminergic neurons , 2003 .

[33]  G. Deuschl,et al.  Force overflow and levodopa-induced dyskinesias in Parkinson's disease. , 2002, Brain : a journal of neurology.

[34]  F. Gage,et al.  Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine , 2000, Brain Research.

[35]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[36]  E. Muñoz,et al.  Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. , 2018, Parkinsonism & related disorders.

[37]  B. Bloem,et al.  CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders , 2015, Front. Neurol..

[38]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[39]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[40]  K. Blennow,et al.  Blood-based NfL A biomarker for differential diagnosis of parkinsonian disorder , 2022 .